Table 1 Participants' characteristics and ART outcome

Number of participants (n)

43

Number of cycles (n)

67

Age (years)

32

(29–37)

AFC

7

(4–13)

Basal FSH (IU/L)

6.1

(5.7–9.9)

AMH (ng/ml)

1.48

(0.29–3.22)

Disease type [n (%)]^a

 Haematological cancers

6

(14.0)

 Breast cancer

22

(51.2)

 Gynecological cancers

3

(7.0)

 Sarcoma

2

(4.7)

 Other cancers

6

(14.0)

 Systemic autoimmune diseases

4

(9.3)

Gonadotroxic treatment [n (%)]^a

 Before fertility preservation

38

(88.4)

 After fertility preservation

5

(11.6)

Stimulation start timing/ stimulation phase [n (%)]^b

 Normal (Day 1–4)

31

(46.3)

 Random (Follicular phase, Luteal phase)

31

(46.3)

 DuoStim

5

(7.5)

LH suppression regimen [n (%)]^b

 GnRH antagonist

27

(40.3)

 PPOS

17

(25.4)

 Others

23

(34.3)

Gonadotropin

 Starting dose of Gonadotropin (IU)

225

(150–300)

 Duration of Gonadotropin use (days)

10

(8–12)

 Total dosage of Gonadotropin use (IU)

2100

(1350–2700)

Triggar [n (%)]^b

 hCG or recombinant hCG

64

(95.5)

 GnRHa

1

(1.5)

 Dual triggar

2

(3.0)

 Serum estradiol on trigger day (pmol/L)

1281.5

(749.3–2044.3)

Outcome of oocyte retrieval

 Number of oocyte retrieved (n)

7

(3–12)

 Number of MII oocytes retrieved (n)

6

(2–11)

 Number of MI oocytes retrieved (n)

0

(0–1)

 Number of GV oocytes retrieved (n)

0

(0–1)

 Mature oocyte rate (%)^c

91.7

(76.3–100)

Method for fertilisation [n (%)]^b

 Conventional insemination

6

(9.0)

 Intracytoplasmic sperm injection

14

(20.9)

 Split

6

(9.0)

 None

41

(61.2)

Embryological outcome

 Fertilisation rate (%)^d

75.0

(57.1–100)

 Cleavage developmental rate (%)^e

85.7

(62.5–100)

 Blastocyst developmental rate (%)^f

87.5

(57.1–100)

Vitrified stage [n (%)]^a

 Oocyte

27

(62.8)

 Blastocyst

16

(37.2)